ScinoPharm Taiwan Ltd Market Cap ($495.76 Million)
Market Cap & Net Worth: ScinoPharm Taiwan Ltd (1789)
ScinoPharm Taiwan Ltd market cap. ScinoPharm Taiwan Ltd (TW:1789) has a market capitalization of $495.76 Million (NT$15.74 Billion) as of November 5, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #11959 globally and #438 in its home market, demonstrating a 0.76% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ScinoPharm Taiwan Ltd's stock price NT$19.90 by its total outstanding shares 790739000 (790.74 Million). Also see 1789 cash flow metrics for how efficiently the company converts equity into cash flow.
ScinoPharm Taiwan Ltd Market Cap History (2015–2026)
ScinoPharm Taiwan Ltd market cap history from 2015 to 2026. Data shows change from $1.22 Billion to $495.76 Million (-4.82% CAGR). Check 1789 stock price and chart for real-time trading data and today's change.
ScinoPharm Taiwan Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ScinoPharm Taiwan Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ScinoPharm Taiwan Ltd net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.13x
ScinoPharm Taiwan Ltd's market cap is 0.13 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.05x
ScinoPharm Taiwan Ltd's market cap is 3.05 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $880.05 Million | $4.03 Billion | $658.69 Million | 0.22x | 1.34x |
| 2017 | $813.45 Million | $3.52 Billion | $422.37 Million | 0.23x | 1.93x |
| 2018 | $562.67 Million | $3.52 Billion | $442.98 Million | 0.16x | 1.27x |
| 2019 | $631.90 Million | $2.89 Billion | $216.66 Million | 0.22x | 2.92x |
| 2020 | $690.92 Million | $3.08 Billion | $282.07 Million | 0.22x | 2.45x |
| 2021 | $602.58 Million | $2.76 Billion | $243.47 Million | 0.22x | 2.47x |
| 2022 | $634.03 Million | $3.26 Billion | $353.22 Million | 0.19x | 1.80x |
| 2023 | $657.69 Million | $3.19 Billion | $287.06 Million | 0.21x | 2.29x |
| 2024 | $549.32 Million | $3.41 Billion | $339.35 Million | 0.16x | 1.62x |
| 2025 | $417.29 Million | $3.16 Billion | $136.95 Million | 0.13x | 3.05x |
Competitor Companies of 1789 by Market Capitalization
Companies near ScinoPharm Taiwan Ltd in the global market cap rankings as of November 5, 2026. Also see 1789 total asset value for a full breakdown of the balance sheet.
Key companies related to ScinoPharm Taiwan Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of ScinoPharm Taiwan Ltd (2015–2026)
Market capitalization of ScinoPharm Taiwan Ltd from 2015 to today. Between 2015 and today, ScinoPharm Taiwan Ltd's market cap moved from $1.22 Billion to $ 495.76 Million, with a yearly change of -4.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$495.76 Million | +18.81% |
| 2025 | NT$417.29 Million | -24.04% |
| 2024 | NT$549.32 Million | -16.48% |
| 2023 | NT$657.69 Million | +3.73% |
| 2022 | NT$634.03 Million | +5.22% |
| 2021 | NT$602.58 Million | -12.79% |
| 2020 | NT$690.92 Million | +9.34% |
| 2019 | NT$631.90 Million | +12.30% |
| 2018 | NT$562.67 Million | -30.83% |
| 2017 | NT$813.45 Million | -7.57% |
| 2016 | NT$880.05 Million | -27.69% |
| 2015 | NT$1.22 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of ScinoPharm Taiwan Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $495.76 Million USD |
| MoneyControl | $495.76 Million USD |
| MarketWatch | $495.76 Million USD |
| marketcap.company | $495.76 Million USD |
| Reuters | $495.76 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ScinoPharm Taiwan Ltd
ScinoPharm Taiwan, Ltd., a pharmaceutical company, provides active pharmaceutical ingredient (API) development and manufacturing and injectable solutions in Taiwan, rest of Asia, Europe, and the Americas. It offers small molecules, peptide drugs, and steroids; drug products for anticancer, thromboembolic disorders, and osteoporosis; and contract analytical testing, sterile injectables contract ma… Read more